Skip to main content
. Author manuscript; available in PMC: 2018 Nov 6.
Published in final edited form as: Mol Pharm. 2017 Oct 3;14(11):4042–4051. doi: 10.1021/acs.molpharmaceut.7b00710

Figure 4. HDL NPs synergize with Ibrutinib to reduce total cellular cholesterol in ABC DLBCL cells.

Figure 4

Total cholesterol of TMD8 (a) and HBL-1 (b) cells treated with Ibrutinib (5nM) in combination with HDL NPs. N=4 for each condition. *p=0.0432 v. PBS control by 2-sided t-test for TMD8 and p=0.0319 v. PBS control by 2-sided t-test for HBL-1. Data presented as mean ± s.e.m.